• Harmony Biosciences Holdings, Inc. reported past first-quarter 2026 results on May 7, with net income of US$32.49 million, down from US$45.56 million a year earlier, and basic earnings per share from continuing operations of US$0.56 versus US$0.79.
• Alongside this earnings miss, the company highlighted 17% net product revenue growth, fresh FDA approval for a pediatric cataplexy indication, and active legal efforts to protect WAKIX patents into 2030.
• We’ll now examine how robust revenue growth alongside lower earnings and ongoing WAKIX patent litigation may influence Harmony’s investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Harmony Biosciences Holdings Investment Narrative Recap

To own Harmony Biosciences today, you need to believe that WAKIX can keep driving meaningful revenue while the company gradually broadens beyond a single core asset. The latest quarter’s lower earnings, despite 17% net product revenue growth, do not materially change the near term focus on WAKIX’s performance and patent protection. The biggest current risk remains Harmony’s heavy dependence on WAKIX and the legal, competitive and pricing pressures tied to that one drug.

Among recent developments, the February FDA approval of WAKIX for pediatric cataplexy looks most relevant, because it potentially widens the narcolepsy patient base that underpins Harmony’s revenue guidance of US$1.0 to US$1.04 billion for 2026. This sits alongside active patent litigation over generic pitolisant, which ties directly into how durable that revenue stream could be while earnings are under pressure in the near term.

Yet beneath the growth headlines, investors should pay close attention to how WAKIX patent disputes and potential generic entry after 2030 could...

Harmony Biosciences Holdings' narrative projects $1.2 billion revenue and $333.5 million earnings by 2028. This requires 17.0% yearly revenue growth and a $152.6 million earnings increase from $180.9 million today.

Uncover how Harmony Biosciences Holdings' forecasts yield a $47.30 fair value, a 54% upside to its current price.

Exploring Other Perspectives

More optimistic analysts were assuming Harmony could lift revenue to about US$1.5 billion and earnings to roughly US$413.9 million, which is far more upbeat than consensus and may look very different once the recent earnings miss and WAKIX focused risks are fully reflected.

Explore 4 other fair value estimates on Harmony Biosciences Holdings - why the stock might be worth just $44.36!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Harmony Biosciences Holdings research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Harmony Biosciences Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harmony Biosciences Holdings' overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.